▎WuXiEdited by Kant Content Team

GSK and Chimagen Biosciences today announced an agreement, under which GSK will...$550 millionAcquisition of CMG1A46, a T-cell engager (TCE) targeting CD19 and CD20, from Chimagen Biosciences.GSK Plans to Develop and Commercialize CMG1A46 for Treating B Cell-Driven Autoimmune Diseases Such as Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN), and is expected to expand to other related autoimmune diseases.GSK Plans to Launch Phase 1 Clinical Trial for Lupus in 2025

Chimagen Biosciences is a clinical-stage biotechnology company focused on discovering and developing novel multispecific T cell engagers and NK cell engagers through its proprietary antibody engineering platform.

CD20 is an established target in the treatment of autoimmune diseases, and clinical evidence increasingly suggests that CD19, due to its expression across a broader range of B cell types, also holds unique therapeutic potential.CMG1A46 is a bispecific antibody designed to simultaneously target CD19 and CD20, featuring an IgG-like molecular structure. It exhibits high affinity for CD19 and CD20 positive B cells while having a lower affinity for CD3, which may help reduce toxicity commonly associated with TCE.In preclinical studies, the therapy demonstrated rapid and deep B-cell depletion in both blood and tissues, potentially offering patients a more durable treatment response.CMG1A46 is currently in Phase 1 clinical trials in the United States and China for the treatment of leukemia and lymphoma patients. GSK plans to initiate a Phase 1 clinical trial for lupus in 2025.

According to the terms of the agreement, GSK will pay a $300 million upfront fee to obtain global full rights to CMG1A46.Chimagen Biosciences is eligible to receive milestone payments for development and commercialization, totaling $550 million.

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline. Retrieved October 29, 2024 from https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-cmg1a46-from-chimagen-biosciences/

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain the reprint guidelines.